<DOC>
	<DOCNO>NCT00749853</DOCNO>
	<brief_summary>Available data vitro study clinical trial indicate genetic factor play significant role success control ovarian stimulation ( COS ) prior vitro fertilization - embryo trandfer ( IVF-ET ) . Women FSHR Ser680Asn Ser/Ser genotype make 13 % 26 % woman undergo IVF-ET characterise high basal FSH serum concentration , need high amount FSH COS , high risk poor response COS cycle cancellation . The investigator therefore intend perform study investigate whether dose-intensified COS protocol base FSHR genotype status woman FSHR Ser680Asn Ser/Ser genotype effective routine management term - mean number follicles - mean number embryo - rate poor responder - rate woman cycle cancellation , v ) clinical pregnancy rate . Eligible woman randomize stimulation protocol characterise long duration increase dosage FSH stimulation ( group A ) standard stimulation protocol ( group B ) .</brief_summary>
	<brief_title>Efficacy Ovarian Stimulation Based FSHR Genotype Status</brief_title>
	<detailed_description>Women group A undergo control ovarian stimulation accord follow protocol : Pituitary down-regulation achieve use buserelin ( Suprefact® , Hoechst , Frankfurt , Germany ) fix daily dose 200 mg s.c. , accord long agonist protocol , start day 2 normal menstrual cycle . Treatment r-hFSH ( Gonal-F® , Serono Austria GmbH , Vienna , Austria ) start woman serum E2 concentration &lt; 200 pmol/l follicle &gt; 15 mm diameter ovarian cyst ultrasonographic examination . The initial r-hFSH dose 250 IU s.c. daily 5 day , dose increase maximum 450 IU per day use step-up protocol step 50 IU/day . Once leading follicle reach diameter 14 mm , patient receive r-hLH ( lutropin alfa ; Luveris® , Serono Austria GmbH , Vienna , Austria ) dose 75 IU s.c. maximum 10 day . A dose 75 IU LH per day choose base finding control , prospective , dose-finding study gonadotrophin-deficient woman ( WHO I classification ) ( 7 ) . Ovulation induce administration HCG ( Profasi® , Serono Austria GmbH , Vienna , Austria ) , 10 000 IU i.m . s.c. , least two follicle reach diameter &gt; 17 mm . Oocyte retrieval perform ultrasound-guided follicular aspiration technique 34-38 h administration HCG . IVF perform accord standard practice institution . A maximum three embryo transfer 48 h oocyte retrieval ( ESHRE Committee Good Clinical Laboratory Practice , 1995 ) . Patients receive micronized progesterone , 600 mg/day , vaginal administration least first 3 week pregnancy , begin day embryo transfer . Women group B undergo ovarian hyperstimulation accord follow protocol : No pituitary down-regulation perform . Treatment r-hFSH ( Gonal-F® , Serono Austria GmbH , Vienna , Austria ) start woman serum E2 concentration &lt; 200 pmol/l follicle &gt; 15 mm diameter ovarian cyst ultrasonographic examination . The r-hFSH dose 150 IU s.c. daily 11 consecutive day . Once leading follicle reach diameter 14 mm , patient receive r-hLH ( lutropin alfa ; Luveris® , Serono Austria GmbH , Vienna , Austria ) dose 75 IU s.c. maximum 10 day . A dose 75 IU LH per day choose base finding control , prospective , dose-finding study gonadotrophin-deficient woman ( WHO I classification ) ( European Recombinant Human LH Study Group , 1998 ) . Ovulation induce administration HCG ( Profasi® , Serono Austria GmbH , Vienna , Austria ) , 10 000 IU i.m . s.c. , least two follicle reach diameter &gt; 17 mm . Oocyte retrieval perform ultrasound-guided follicular aspiration technique 34-38 h administration HCG . IVF perform accord standard practice institution . A maximum three embryo transfer 48 h oocyte retrieval ( ESHRE Committee Good Clinical Laboratory Practice , 1995 ) . Patients receive micronized progesterone , 600 mg/day , vaginal administration least first 3 week pregnancy , begin day embryo transfer .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<mesh_term>Buserelin</mesh_term>
	<criteria>Age 18 40 Informed consent Indication IVFET Inability understand write informed consent form Personal history ovarian hyperstimulation syndrome</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>ovarian stimulation</keyword>
	<keyword>FSH</keyword>
	<keyword>genotyping</keyword>
	<keyword>polymorphism</keyword>
</DOC>